Inhibikase Therapeutics (Inhibikase Therapeutics) Equity-to-Asset : 0.61 (As of Mar. 2024)

Inhibikase Therapeutics Equity-to-Asset Chart

Inhibikase Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Equity-to-Asset	Get a 7-Day Free Trial															0.90	0.87	0.84	0.76	0.61

Competitive Comparison of Inhibikase Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Inhibikase Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inhibikase Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Inhibikase Therapeutics's Equity-to-Asset falls into.

Inhibikase Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Inhibikase Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Inhibikase Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inhibikase Therapeutics  (NAS:IKT) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Inhibikase Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Inhibikase Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibikase Therapeutics (Inhibikase Therapeutics) Business Description